Trial shows offering prostate cancer drug earlier improves survival
Tuesday, 22nd August 2017
According to results from the Cancer Research UK-funded STAMPEDE clinical trial, offering abiraterone plus prednisolone in combination with standard therapy to men with prostate cancer earlier, before the disease becomes resistant to standard hormone therapy, can help boost survival.
Click the following link to read the rest of the article on the Cancer Research Blog http://scienceblog.cancerresearchuk.org/2017/06/06/once-in-a-career-feeling-as-trial-shows-offering-prostate-cancer-drug-earlier-improves-survival/?utm_campaign=bl_AugustEnews_030817_ccmpe&utm_source=ccmp&utm_medium=email&cid=61844&mid=150711173
No upcoming events.
OWise Announce Launch of Prostate Cancer App
29 Mar 2021